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Background. 𝛼-Synuclein (SNCA) and microtubule-associated protein tau (MAPT) are the two major genes independently, but
not jointly, associated with susceptibility for Parkinson’s disease (PD). The SNCA gene has recently been identified as a major
modifier of age of PD onset.WhetherMAPT gene synergistically influences age of onset of PD is unknown.Objective. To investigate
independent and joint effects of MAPT and SNCA on PD onset age. Methods. 412 patients with PD were recruited from the
Australian PD Research Network (123) and the Neurology Department, Ruijin Hospital Affiliated to Shanghai Jiaotong University,
China (289).MAPT (rs17650901) tagging H1/H2 haplotype and SNCA (Rep1) were genotyped in the Australian cohort, andMAPT
(rs242557, rs3744456) and SNCA (rs11931074, rs894278) were genotyped in the Chinese cohort. SPSS regression analysis was used
to test genetic effects on age at onset of PD in each cohort. Results. SNCA polymorphisms associated with the onset age of PD in
both populations.MAPT polymorphisms did not enhance such association in either entire cohort. Conclusion. This study suggests
that, in both ethnic groups, SNCA gene variants influence the age at onset of PD and 𝛼-synuclein plays a key role in the disease
course of PD.
1. Introduction
Parkinson’s disease (PD) is the most common neurodegen-
erative movement disorder in the elderly (approximately 2%
of the population aged over 60) with an average age of onset
of 60 years and a variety of different subtypes [1, 2]. Patients
with young disease onset often have a benign disease course
and a lower rate of dementia compared to those with later
disease onset [3], and previous studies show that genetic
factors influence both the age of onset [4, 5] and clinical
subtypes of PD [6–8]. These clinical variations are not due
to mutations in PD causative genes [9].
The two most consistently identified susceptibility
genes for sporadic PD are the 𝛼-synuclein (SNCA) and
microtubule-associated protein tau (MAPT) genes [10, 11]
which play independent, but not joint, effects on the risk
of developing PD [12, 13], although there are significant
differences in the variants associated with PD between
Asian and Caucasian populations [14]. In addition, we have
shown that in Caucasians the SNCA and MAPT genes act
synergistically to influence the rate of progression of PD
(certain genotypes have a 5.8-increased risk for developing
a more rapid disease progression) when analysing one
microsatellite (Rep1 or D4S3481 with three common alleles,
that is, 259 bp, 261 bp, and 263 bp or alleles 0, 1, and 2) marker
of SNCA gene and a rs17650901 SNP of MAPT gene (lies in
exon 1 and its A-allele tags the MAPT H1 haplotype [15]) in
an Australian cohort [7]. A recent study showed that among
17 genome-wide association studies- (GWAS-) linked loci in
mainland China, only two SNPs (rs11931074 and rs894278)
of the SNCA gene associate with the risk for sporadic PD
after adjusting for age and sex [16]. The rs894278 SNP is
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Table 1: Subjects demographic information.
PD cohorts 𝑁 Female :male Ethnic origin Age (y/o) (mean ± SD)∗ Onset (mean ± SD)
Australians 123 57 : 66 Caucasian 68 ± 9 60 ± 11
Chinese 289 119 : 170 Han 63 ± 9 58 ± 10
𝑁: number; y/o: years old; SD: standard deviation; ∗𝑃 < 0.001.
located in intron 4, and the rs11931074 remains distal to the
untranslated region of SNCA [17]. The MAPT gene does
not appear to be associated with PD susceptibility in the
Chinese [16], possibly due to ethnicity and the extremely low
frequency of the H2 MAPT haplotype in mainland China
[18]. However, the MAPT H1c subhaplotype (tagged by the
rs242557 A-allele [19]) and other SNPs (e.g., rs3744456) are
associated with increased expression of tau (especially four
repeat transcripts) in human brain tissue [20, 21] and in vivo
experiments [22]. These different MAPT SNPs might be
associated with PD risk in the Chinese.
It has recently been shown that the SNCA gene is a
major modifier of age of PD onset [23]. However it remains
unclear whether the MAPT gene also modified age of PD
onset and whether there is a synergistic effect of both
SNCA and MAPT on the age of onset of PD. This study is
to investigate independent and joint effects of MAPT and
SNCA on PD onset age. Understanding the influence of
variations in these genes on clinical features of PD in different
ethnic populations would further consolidate the molecular
pathophysiologic mechanisms underpinning PD.
2. Methods
2.1. Study Subjects. 412 patients satisfying the Queen Square
Brain Bank Criteria for PD and without autosomal dominant
family history of PD were recruited consecutively from the
Australian Parkinson’s Disease Research Network, Australia
(Caucasian: 𝑛 = 123, 66 male, 57 female) and the movement
disorders clinic, Department of Neurology, Ruijin Hospital
Affiliated to School of Medicine, Shanghai Jiaotong Univer-
sity, China (Han: 𝑛 = 289, 170 male, 119 female) (Table 1).
The average age at recruitment (± standard deviation) was
68 ± 9.0 years in Australia and 63 ± 9.4 years in China.
The studies were approved by the appropriate institutional
ethics committees of the University of New South Wales and
the School of Medicine, Shanghai Jiaotong University. Blood
fromeach patientwas takenwith consent for genetic analyses.
Genomic DNA was extracted from peripheral blood by a
standardized phenol/chloroform extraction method.
2.2. Clinical Information. At recruitment, a standard ques-
tionnaire was completed to obtain detailed clinical infor-
mation, such as gender, age at onset, age at enrolment,
medication administration, and family history. The age of
onset of PD was defined when at least two of the three
main signs of PD, that is, rigidity, tremor, and bradykinesia,
had developed [24]. The average age at onset (±standard
deviation) was 60 ± 11 years in the Australian cohort (range
32–83 years) and 58 ± 10 years in the Chinese cohort (range
34–82 years).
2.3. Genetic Analysis. Due to population-specific hetero-
geneity in PD [25], MAPT (rs17650901) and SNCA Rep1
(D4S3481) were genotyped in the Australian cohort [7,
15, 26], and MAPT (rs2425577 and rs3744456) and SNCA
(rs11931074, rs894278) were genotyped in the Chinese cohort
[22] (see supplementary Table 1 in supplementary material
available online at http://dx.doi.org/10.1155/2015/135674).The
rate of genotype calls was ≥95% for all SNPs. For those
variants identified by restriction fragment length polymor-
phism (RFLP), the genotype results were further confirmed
via direct PCR product sequencing on random samples. An
online tool (http://www.genes.org.uk/software/cubex/) [27]
was used to assess linkage disequilibrium in the selected
SNPs.
2.4. Statistical Analyses. Differentmodels of inheritance were
adopted for analysing each polymorphic effect on age at
PD onset using one-way ANOVA, where onset age was
considered as a continuous variable. As more males have
PD, SPSS regression analyses were then used adjusting for
gender to minimize this effect. After examining the effects
of single polymorphisms on onset age in all subjects, gene-
gene interactions were assessed in each cohort using adjusted
regression models, and a 𝑃 value of <0.05 was considered as
significant.
3. Results
Our results showed that the SNCA gene, but not the MAPT
gene, associated with age of PD onset in the cohorts assessed.
No synergic genetic effects were detected on age of PD
onset between SNCA and MAPT polymorphisms in either
the Australian or Chinese cohort. There was a weak linkage
disequilibriumbetween SNCA rs11931074 and rs894278 (𝐷󸀠 =
0.72) and there was no linkage disequilibrium between
MAPT rs2425577 and rs3744456 (𝐷󸀠 = 0.44) in the Chinese
cohort.
3.1. SNCA, but Not MAPT Gene, Associates with Age of PD
Onset. SPSS-ANOVA analysis showed that polymorphisms
in SNCA only, but not MAPT gene, associated with the age
of onset of PD in both populations sampled (Table 2). In the
Australian cohort, the genotype of SNCAD4S3481 associated
with onset age of PD.The genetic associations were consistent
with recessive models of inheritance of SNCA D4S3481 allele
1, althoughdominant and additivemodels of allele 0 and allele
1 also had significant effects on the age of PD onset (Table 2).
BioMed Research International 3
Table 2: SNCA but notMAPT gene associates with age of PD onset (Random-Effects Models).





Genotypes (00, 01, 02, 11, 12, 22) 14, 34, 6, 51, 15, 3 3.953 0.002
Allele 0 carrier status (2, 1, 0) 14, 40, 69 5.606 0.005
Dominant (2 + 1, 0) 54, 69 11.291 0.001
Recessive (2, 1 + 0) 14, 109 1.996 0.160
Allele 1 carrier status (2, 1, 0) 51, 49, 23 8.408 <0.001
Dominant (2 + 1, 0) 100, 23 8.742 0.004
Recessive (2, 1 + 0) 51, 72 13.840 <0.001
Allele 2 carrier status (2, 1, 0) 3, 21, 99 1.966 0.145
∗Dominant (2 + 1, 0) 24, 99 1.853 0.176
MAPT





Dominant (GG + GT versus TT) 172 versus 117 0.638 0.425
Recessive (GG versus GT + TT) 46 versus 243 0.358 0.550
Additive (GG versus GT versus TT) 46 versus 126 versus117 0.374 0.689
rs894278
Dominant (GG + GT versus TT) 182 versus 107 0.665 0.415
Recessive (GG versus GT + TT) 47 versus 242 5.20 0.023
Additive (GG versus GT versus TT) 47 versus 135 versus107 2.592 0.077
MAPT
rs2425577
Dominant (GG + GA versus AA) 190 versus 99 0.583 0.446
Recessive (GG versus GA + AA) 55 versus 234 0.026 0.871
Additive (GG versus GA versus AA) 55 versus 135 versus99 0.297 0.744
∗rs3744456 Dominant (CC + CG versus GG) 77 versus 212 1.574 0.211
∗Only dominant inheriting pattern is adopted due to rare minor allele frequency of the homozygote.
Table 3: Association between SNCA and age of onset of Parkinson’s disease after adjusting for gender.
Cohorts Polymorphism 𝑁 Genetic Inheritance Model Genotype 𝑁 Age at onset (s.e.) 𝑃 value
Australians SNCA D4S3481 123 Recessive No allele 1-one allele 1 72 57 (12) 0.002
Two allele 1 51 64 (8)
Chinese SNCA rs894278 289 Recessive G/G 47 55 (2) 0.015
T/T-G/T 242 58 (1)
𝑁 = number; s.e. = standard error.
In the Chinese cohort, only SNCA rs894278 SNP associated
with PD onset age, which followed a recessive inheritance
model for allele G.
3.2. Genetic Effects of SNCAGene onAge of Onset of PD. After
adjusting for gender, SPSS regression analysis showed that
SNCA polymorphisms were still associated with the onset age
of PD, although the effect observed for the SNCA D4S3481
allele 1 in Australians is more obvious compared with the
SNCA rs894278 SNP in the Chinese. Australians carrying two
SNCA D4S3481 allele 1 had a delayed onset of PD by about
seven years (𝑃 = 0.002), while the Chinese with a SNCA
rs894278 GG genotype had an earlier onset by about three
years (𝑃 = 0.015) (Table 3 and supplementary figure).
4. Discussion
Whether a person might develop PD (susceptibility of PD)
and when a patient with PD starts to show the symptoms
(PD onset) are two distinct questions. It is not surprising that
the data derived from two distinct ethnic cohorts show that
polymorphisms in the SNCA gene can influence the age of
PD onset, while polymorphisms in the MAPT gene do not,
although MAPT gene has been shown directly or indirectly
(by regulating other PD risk genes) to be associated with PD
in both populations [28–30].
Our data showing that the SNCA gene affects age of PD
onset in Australian and Chinese cohorts is consistent with
a recent report using a very large sample cohort [23] and
also with other similarly sized population studies in Spain
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[31], Germany [23], the UK [13], and Greece [32]. The effect
of the SNCA gene on age of PD onset is even observed in
patients carrying leucine rich repeat kinase 2 (LRRK2) gene
mutations [33]. There is stronger SNCA gene effects on PD
onset age in the Australians compared to that in the Chinese,
possibly due to the testing of different polymorphisms, as
previously shown [34, 35]. In different populations, the same
polymorphism of SNCA seems to have variable strengths of
effects on PD onset [36], possibly due to other modifiers.
Identifying genes associating with onset of PD has poten-
tial for therapeutic targeting. If interventions could delay the
onset of symptoms, for some this may effectively “cure” their
disease by delaying symptom onset to beyond their life span,
while for others it would significantly reduce morbidity and
enhance the quality and productivity of their life.
Expression data show that compared to SNCA “pro-
tective” alleles D4S3481 allele 0 (259 bp) [37] and another
allele 2 (263 bp) [38], SNCA gene expression is increased
in carriers of the SNCA D4S3481 allele 1 (261 bp). Our data
showed a seven-year delay in the disease onset in carriers
with two allele 1 of SNCA D4S3481 (Table 3). While the
biological function of SNCA rs894278 G allele remains to be
determined, the SNCA rs11931074 allele T is associated with
reduced serum 𝛼-synuclein [39], even though it is actually
located distal to the 3󸀠UTR sequence. Due to theweak linkage
disequilibrium of SNCA rs11931074 and rs894278, it indicates
that the SNCA rs894278 GG genotype may also reduce SNCA
gene expression. Our data showed that SNCA rs894278 GG
genotype carriers have an earlier PD onset by three years on
average (Table 3). In summary, our combined genetic data
indicated the expression levels of SNCA play an important
role at the onset age of PD with lower SNCA expression
associated with earlier onset and the higher SNCA expression
associated with older PD onset.
In PD, different PD susceptibility genes occur in early
onset compared with late onset of PD [40, 41], and theMAPT
gene did not independently influence the age of PDonset [13].
Although𝛼-synuclein fibrillisation and Lewy body formation
in human brain are the key and essential pathogenic process
in PD, substantial loss of dopaminergic neurons ismore likely
responsible for the onset of the clinical motor symptoms
diagnostic of PD. Recent evidence suggests 𝛼-synuclein is
a critical protein in dopaminergic neuron survival. During
normal ageing, increased SNCA expression in the brain has
been observed in both healthy humans and monkeys [42].
Interestingly, increased SNCA expression is associated with
an increased lifespan in transgenic C. elegans [43] and SNCA
variants are associated with an increase in human lifespan
[44]. These data may suggest that a reduction in biologi-
cally functional 𝛼-synuclein, whether through aggregation or
reduced expression, could precipitate the neurodegeneration
in PD [45, 46].
The merit of this study is the interrogation of two
populations independently, with comparable results in both
cohorts. Our data suggest that different therapeutic strategies
should be considered based on polymorphisms in the SNCA
gene of individual patients and that maintaining a certain
level of biologically functional 𝛼-synuclein is an important
consideration in targeting 𝛼-synuclein for therapies [44, 47].
Our results emphasize that a better understanding of
genome-wide risk factors on the clinical quantitative traits in
patient with PD, that is, age at onset and severity of motor
and nonmotor symptoms,may assist with future personalised
medicine for PD.
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